Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Integrated securement dressings vs standard polyurethane Occlusion assessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | no estimate extracted | 1 study · 105 participants | Low |
Standard polyurethane plus tissue adhesive vs standard polyurethane Incidence of catheter‐related bloodstream infection assessed during catheter dwell or 48 hours after removal · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | no estimate extracted | 2 studies · 165 participants | Very low |
Integrated securement dressings vs standard polyurethane Adverse events assessed during catheter dwell or on product removal · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.35 [0.01, 8.45] | 1 study · 105 participants | Low |
Standard polyurethane plus tissue adhesive vs standard polyurethane Dislodgement assessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.54 [0.03, 9.62] | 2 studies · 165 participants | Very low |
Standard polyurethane plus tissue adhesive vs standard polyurethane Occlusion assessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 1.2 [0.37, 3.91] | 2 studies · 165 participants | Very low |
Standard polyurethane plus tissue adhesive vs standard polyurethane Adverse events assessed during catheter dwell and on product removal · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.89 [0.09, 8.33] | 2 studies · 165 participants | Very low |
Bordered polyurethane vs standard polyurethane Arterial catheter failureassessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.67 [0.21, 2.13] | 1 study · 60 participants | Very low |
Bordered polyurethane vs standard polyurethane Incidence of catheter‐related bloodstream infectionassessed during catheter dwell or 48 hours after removal · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 3.05 [0.12, 74.45] | 2 studies · 572 participants | Low |
Bordered polyurethane vs standard polyurethane Dislodgement assessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.75 [0.17, 3.22] | 2 studies · 572 participants | Low |
Bordered polyurethane vs standard polyurethane Occlusion assessed during catheter dwell · people with arterial catheter dressing and securement Dressings and securement devices to prevent complications for peripheral arterial catheters (2024) · Cochrane | RR 0.8 [0.6, 1.07] | 2 studies · 572 participants | Low |
Exposure vs no exposure to the smell and taste of milk with tube feeds Time to reach full sucking feeds (time to removal of the feeding tube) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | no estimate extracted | 3 studies · 662 participants | Very low |
Exposure vs no exposure to the smell and taste of milk with tube feeds Adverse effects related to intervention · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | no estimate extracted | 2 studies · 2 participants | Ungraded |
Exposure vs no exposure to the smell and taste of milk with tube feeds Duration of parenteral nutrition (time to removal of IV nutrition line) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | no estimate extracted | 3 studies · 977 participants | Low |
Exposure vs no exposure to the smell and taste of milk with tube feeds Time to reach full enteral feeds (150 mL/kg/day or as defined by the trialists) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | no estimate extracted | 4 studies · 736 participants | Very low |
Exposure vs no exposure to the smell and taste of milk with tube feeds Feeding intolerance during hospitalisation (resulting in discontinuation of or reduction in enteral feeding) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Exposure vs no exposure to the smell and taste of milk with tube feeds Necrotising enterocolitis during hospitalisation (Bell's stage ≥ 2) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | RR 0.93 [0.47, 1.84] | 2 studies · 435 participants | Low |
Exposure vs no exposure to the smell and taste of milk with tube feeds Late infection during hospitalisation (bacterial or fungal infection confirmed by presence of blood or CSF infection, with initiation of symptoms > 48 hours after birth) · preterm infants Exposure to the smell and taste of milk to accelerate feeding in preterm infants (2024) · Cochrane | RR 1.14 [0.74, 1.75] | 2 studies · 436 participants | Moderate |
Manual therapy, prescribed exercises or both vs placebo PainScale: numerical rating scale (0 to 10, 0 is no pain) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 1 study · 23 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Health‐related quality of lifefScale: SF‐36 (0 to 100, 100 indicates perfect health) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 2 studies · 113 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Participant‐reported treatment success · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 1.36 [0.96, 1.93] | 6 studies · 770 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion of overall withdrawals · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 0.86 [0.66, 1.12] | 12 studies · 1147 participants | Very low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion with any adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 3.69 [0.98, 13.97] | 6 studies · 457 participants | Very low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion with a serious adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 1 study · 23 participants | Low |
Manual therapy, prescribed exercises or both vs placebo Quality of life · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Participant‐reported treatment success · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion of withdrawals · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion with adverse events · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion with a serious adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs minimal or no intervention PainScale: VAS (0 to 10, 0 is no pain) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 12 studies · 1023 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention DisabilityScale: Disability questionnaires (0 to 100, 0 is no disability) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 10 studies · 732 participants | Low |
Any psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up Depressive symptomatology (lower = less depressive symptomatology): end‐of‐intervention · older people with depression Psychological therapies for depression in older adults residing in long‐term care settings (2024) · Cochrane | no estimate extracted | 18 studies · 644 participants | Very low |
Any psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up Treatment non‐acceptability (higher = greater non‐acceptability): end‐of‐intervention · older people with depression Psychological therapies for depression in older adults residing in long‐term care settings (2024) · Cochrane | no estimate extracted | 5 studies · 313 participants | Very low |
Any psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up Depression remission (presence or absence of MDD):end‐of‐intervention · older people with depression Psychological therapies for depression in older adults residing in long‐term care settings (2024) · Cochrane | no estimate extracted | 1 study · 82 participants | Very low |
Any psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · older people with depression Psychological therapies for depression in older adults residing in long‐term care settings (2024) · Cochrane | no estimate extracted | 6 studies · 195 participants | Very low |
Any psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up Anxious symptomatology (lower = less anxious symptomatology): end‐of‐intervention · older people with depression Psychological therapies for depression in older adults residing in long‐term care settings (2024) · Cochrane | no estimate extracted | 2 studies · 115 participants | Very low |
Testosterone vs placebo Erectile function · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 3 studies · 792 participants | Moderate |
Testosterone vs placebo Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | RR 1.04 [0.58, 1.86] | 2 studies · 122 participants | Very low |
Testosterone vs placebo Prostate‐related events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Erectile function · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Testosterone vs PDE5I Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Testosterone vs PDE5I Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Prostate‐related events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Testosterone vs placebo Erectile function · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 6 studies · 2016 participants | Moderate |
Testosterone vs PDE5I Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone as an add‐on to PDE5I vs PDE5I alone Erectile function (conversion to IIEF‐EF) · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 4 studies · 430 participants | Low |